Business Wire
13 Sept 2026, 23:15 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
1 claim · each scored for market impact
Taiho Oncology and Cullinan Therapeutics announced Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in first-line EGFR ex20ins mutation-positive NSCLC. — Phase 3 trial results for a first-line cancer treatment are primary value drivers for biotech firms like Cullinan Therapeutics (CGEM).
+0.40Which stocks this story touches
The company announced Phase 3 trial results for zipalertinib, a key pipeline asset.
Continue reading
5 related stories
Search tags
Read next
PRNewsWire · 2h ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
17h ago
